Abstract
Amgen has agreed to buy Horizon Therapeutics, a Dublin-based biotech specializing in medicines for rare, autoimmune, and severe inflammatory diseases, for about $27.8 billion in cash. It is the highest price tag of any merger in the pharmaceutical industry this year. Horizon had previously been in talks with Sanofi and Johnson & Johnson. “The acquisition builds on Amgen’s success in rare diseases and provides a strong platform for us to expand in this space in the future,” Amgen CEO Robert A. Bradway said on a Dec. 12 conference call with stock analysts. Amgen, which markets blockbuster medicines like Otezla for plaque psoriasis and Aimovig for migraines, will receive Horizon’s Tepezza and Uplizna, both monoclonal antibodies, and Krystexxa, an enzyme. Those three drugs, all for rare diseases, garnered $2 billion in sales in the first 9 months of 2022, Bradway said. Horizon also has several candidates in the clinic for various
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
